Adam Schayowitz Biography and Net Worth

Executive Vice President and Head of R&D of Zymeworks

Dr. Schayowitz has served as our Executive Vice President and Head of Research and Development since April 2026. He previously served as our Acting Chief Development Officer from October 2025 to March 2026. Dr. Schayowitz brings nearly 20 years of experience in oncology drug development to Zymeworks, having led dozens of global development programs from initiation through approval and commercialization. Prior to joining EcoR1 as an Operating Partner, he was a Vice President at Pfizer Oncology holding various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in serving as Head of Product Development Teams. Prior to Pfizer, Dr. Schayowitz led the development of Zejula (niraparib) at Tesaro and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo (Radium-223). He is currently a Board Member at Terremoto Biosciences and serves as a Board Observer for Aktis Oncology. Dr. Schayowitz has a BA from Hamilton College, a Ph.D. in Pharmacology from The University of Maryland, and an MBA from Johns Hopkins.

What is Adam Schayowitz's net worth?: The estimated net worth of Adam Schayowitz is at least $598.46 thousand as of October 9th, 2026. Dr. Schayowitz owns 23,205 shares of Zymeworks stock worth more than $598,457 as of October 12th. This net worth evaluation does not reflect any other investments that Dr. Schayowitz may own. Learn More about Adam Schayowitz's net worth.
How do I contact Adam Schayowitz?: The corporate mailing address for Dr. Schayowitz and other Zymeworks executives is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Adam Schayowitz's contact information.
Has Adam Schayowitz been buying or selling shares of Zymeworks?: During the past quarter, Adam Schayowitz has sold $357,557.20 in shares of Zymeworks stock. Most recently, Adam Schayowitz sold 13,832 shares of the business's stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a transaction totalling $357,557.20. Following the completion of the sale, the executive vice president now directly owns 23,205 shares of the company's stock, valued at $599,849.25. Learn More on Adam Schayowitz's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Adam Schayowitz (Executive Vice President and Head of R&D), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last year, insiders at the sold shares 9 times. They sold a total of 201,765 shares worth more than $5,031,273.24. The most recent insider tranaction occured on October, 9th when EVP Adam Schayowitz sold 13,832 shares worth more than $357,557.20. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 10/9/2026.

Adam Schayowitz Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/9/2026	Sell	13,832	$25.85	$357,557.20	23,205

Adam Schayowitz Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $25.62

$25.56

$25.79

50 Day Range

MA: $26.64

$21.81

$31.05

2 Week Range

Now: $25.62

$16.00

$31.34

Volume

6,501 shs

Average Volume

705,366 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17